Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Assistant Cancer Center Director for Education and Training

Physician Biography


Dr. Kluger is a medical oncologist who sees patients with melanoma, renal cell carcinoma and breast cancer. Her research interests focus on developing new drugs and biomarkers predictive of response to these drugs in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs and active research laboratory that studies tumors and cells from patients treated with novel therapies.

Clinical Interests

  • Breast Diseases
  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center: Melanoma Program | Prostate and Urologic Cancers Program

General Adult Urology

Medical Oncology

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine)

  • Medical Oncology AB of Internal Medicine (2002)

Clinical Trials

Conditions Study Title
Breast - Female, Colon, Kidney, Melanoma, skin, Rectum, Phase I Testing safety & tolerability of MEDI4736 with Tremelimumab in Solid Tumors
Melanoma, skin S1404: Ph III trial Comparing High Dose Interferon to MK-3475 in Pts w/ High Risk Resected Melanoma
Brain and Nervous System, Lung, Melanoma, skin Pembrolizumab and bevacizumab in untreated brain metastases
Kidney, Lung, Melanoma, skin, Phase I A phase 1/2 Dose escalation and expansion study of NKTR-214 in patients with adv. or met. tumors
Melanoma, skin Study Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 Metastatic Melanoma
Melanoma, skin Refractory B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Exhibits B7-H3 Neoplasms
Colon, Melanoma, skin, Phase I Phase 1 Study of CM-24 (MK-6018) in Subjects with Selected Advanced or Recurrent Malignancies
Kidney, Phase I Phase 1 study of safety & pharmacology with locally advanced or metastatic solid tumors
Melanoma, skin, Phase I Varlilumab and Nivolumab in advanced refractory solid tumors
Soft Tissue, Phase I Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 & Mogamulizumab in Combinati
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Melanoma, skin Stand Up To Cancer
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Kidney Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid, Phase I PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Harriet Kluger, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste North Pavilion 4

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520-8028